Caplacizumab-yhdp (Cablivi®)

Caplacizumab‑yhdp (Cablivi) is covered only for adults (≥18) with acquired TTP when used in combination with plasma exchange and concurrent immunosuppressive therapy and must be initiated in the inpatient setting; use outside this indication or without meeting the criteria is not supported. Approval (up to 2 months) requires documentation of diagnosis, current immunosuppressive therapy, hematology prescriber/consult, inpatient initiation with plasma exchange, adherence to the dosing schedule (11 mg IV ≥15 minutes before first exchange then 11 mg SC after exchange on day 1 and daily SC after subsequent exchanges), no more than 60 doses after the last plasma exchange, and ≤2 recurrences while on prior Cablivi if applicable.

"Cablivi is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy."